echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > JAMA Netw Open: Assessment of first and second waves of SARS-CoV-2 seroprevalence among Canadian adults in 2020 and 2021

    JAMA Netw Open: Assessment of first and second waves of SARS-CoV-2 seroprevalence among Canadian adults in 2020 and 2021

    • Last Update: 2022-03-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Importance: The incidence of infection during SARS-CoV-2 viral waves, factors associated with infection, and the persistence of antibody responses to infection in Canadian adults remain undocumented
    .

    The incidence of infection during SARS-CoV-2 viral waves, factors associated with infection, and the persistence of antibody responses to infection in Canadian adults remain undocumented
    .


    Objective: To assess the cumulative incidence of SARS-CoV-2 infection during the first two waves of viral infection in Canada by measuring adult seroprevalence
    .

    Design, settings and participants: Beating the Coronavirus Action Research conducted two rounds of online surveys on COVID-19 experience and analyzed immunoglobulin G levels based on dried blood spots collected by participants to assess first and second waves in Canada Cumulative incidence of SARS-CoV-2 infection during the virus
    .


    A sample of 19,994 Canadian adults (age? 18) was recruited from regular members of the public polling organization Angus Reid Forum


    Main outcomes and measures: SARS-CoV-2 immunoglobulin G seropositivity (using chemiluminescence) and association with reporting of COVID-19 symptoms for key geographic and demographic variables
    .

    RESULTS: Among the 19,994 adults who completed the online questionnaire in Phase 1, the mean age (SD) was 50.
    9 years (15.
    4 years), and 10,522 (51.
    9%) were female; 2,948 (14.
    5%) had Self-identified racial and ethnic minority status, 1578 participants (8.
    2%) were self-identified Aboriginal Canadians
    .


    Of the participants in the first phase, 8967 were tested for DBS


    Figure 1.
    Comparison of Weekly Averages of COVID-19 Confirmed Cases and Vaccinations between Study Phases 1 to 3 and Canada from March 1, 2020 to December 1, 2021

    Figure 1.
    Comparison of Weekly Averages of COVID-19 Confirmed Cases and Vaccinations between Study Phases 1 to 3 and Canada from March 1, 2020 to December 1, 2021

    Table 1.
    Seroprevalence of SARS-CoV-2 in Canada's first and second waves and factors associated with second wave infection

    Table 1.
    Seroprevalence of SARS-CoV-2 in Canada's first and second waves and factors associated with second wave infection

    Table 2.
    Factors associated with second-stage seropositive, asymptomatic, and symptomatic SARS-CoV-2 infection

    Table 2.
    Factors associated with second-stage seropositive, asymptomatic, and symptomatic SARS-CoV-2 infection

    Figure 2.
    Monthly Persistence of Immunoglobulin G Antibodies Between Phase I and Phase II Sample Collection

    Figure 2.
    Monthly Persistence of Immunoglobulin G Antibodies Between Phase I and Phase II Sample Collection

    Table 3.
    Age distribution of first and second waves of SARS-CoV-2 infection, death, and infection mortality in Canada

    Table 3.
    Age distribution of first and second waves of SARS-CoV-2 infection, death, and infection mortality in Canada

    Conclusions: The Action Against Coronavirus Study found that the incidence of SARS-CoV-2 infection in Canada was modest until March 2021 and that this incidence was below the level of population immunity required to substantially reduce virus transmission
    .


    Ongoing vaccination efforts remain central to reducing virus transmission and mortality


    The Action Against Coronavirus Study found that until March 2021, the incidence of SARS-CoV-2 infection in Canada was modest and below the level of population immunity needed to substantially reduce the spread of the virus


    Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults.
    JAMA Leave a Comment
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.